Ronald A. Booth
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ronald A. Booth has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
Christopher R. McCudden
Division of Biochemistry, The Ottawa Hospital and Department of Pathology & Laboratory Medicine, University of Ottawa, Ottawa, ON, Canada
2 shared publicationsMark S. Freedman
University of Ottawa, Department of Medicine, Neurology and the Ottawa Hospital Research Institute, Ottawa, ON, Canada
2 shared publicationsAleksandra Maleska Maceski
Multiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland; Department of Neurology, University Hospital and University of Basel, Basel, Switzerland
1 shared publicationAmy H. Lou
Department of Pathology and Laboratory Medicine, Nova Scotia Health Authority- Central Zone, Dalhousie University, Halifax, NS, Canada
1 shared publicationAndrea Thoni
Nova Scotia Health Authority, Department of Pathology and Laboratory Medicine, Halifax, NS, Canada
1 shared publicationArleigh McCurdy
Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada
1 shared publication
Latest Publications
- Open Access
- 23 June 2025
- Published by Elsevier in Clinica Chimica Acta
- Vol. 577, 120447
Validation and generation of age-specific reference intervals for a new blood neurofilament light chain assay
- 23 June 2025
- Published by Elsevier in Clinica Chimica Acta
- Vol. 577, 120447
Open AccessValidation and generation of age-specific reference intervals for a new blood neurofilament light chain assay
- Open Access
- 25 November 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-9
The combination of CSF neurofilament light chain and glial fibrillary acidic protein improves the prediction of long-term confirmed disability worsening in multiple sclerosis
Our objective was to evaluate the individual and combined prognostic attributes of baseline serum and CSF measurements of Neurofilament light chain (sNfL, cNfL) and glial fibrillary acidic protein (sGFAP, cGFAP) on long term clinical outcomes in MS. In this retrospective single center study, patients with serum and CSF stored at first MS presentation and > 15-years of follow-up were analyzed. NfL and GFAP were quantified from cryopreserved samples using a digital immunoassay and analyzed as predictors of confirmed disability worsening (CDW). Sixty patients (70% female) underwent baseline tandem CSF and serum sampling and were followed for a mean of 17.8 years (SD 2.5). 32 developed CDW. By logistic regression, while sNfL cNfL and cGFAP showed prognostic merit (AUC 0.72, 0.70, 0.62 respectively), sGFAP did not (AUC 0.5). The combination of cNfL and cGFAP improved CDW prediction compared to either measure considered in isolation (AUC 0.72). The optimal predictive cut-off for CDW (Youden’s index) for cNfL was 596 pg/mL and for cGFAP was 8160 pg/mL. Kaplan–Meier analysis of the cutoff-defined ‘high-high’ and ‘low-low’ combined cNfL and cGFAP groupings improved prediction of CDW compared to either marker individually (Hazard ratio 4.5 (95% CI 2.7–18.3), Logrank P < 0.0001). Cox Proportional Hazards regression demonstrated that high baseline cNfL and cGFAP were independently prognostic of subsequent CDW after adjusting for baseline age, sex, EDSS score and subsequent treatment exposure. Each unit increase in Ln(cNfL) and Ln(cGFAP) was respectively associated with an additional hazard of 2.36 (95% CI 1.12–5.52) and 2.26 (95% CI 1.03–5.21). CSF NfL and GFAP are independently prognostic of long-term clinical worsening in MS, and may represent a complementary pairing.
- 25 November 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-9
Open AccessThe combination of CSF neurofilament light chain and glial fibrillary acidic protein improves the prediction of long-term confirmed disability worsening in multiple sclerosis
Our objective was to evaluate the individual and combined prognostic attributes of baseline serum and CSF measurements of Neurofilament light chain (sNfL, cNfL) and glial fibrillary acidic protein (sGFAP, cGFAP) on long term clinical outcomes in MS. In this retrospective single center study, patients with serum and CSF stored at first MS presentation and > 15-years of follow-up were analyzed. NfL and GFAP were quantified from cryopreserved samples using a digital immunoassay and analyzed as predictors of confirmed disability worsening (CDW). Sixty patients (70% female) underwent baseline tandem CSF and serum sampling and were followed for a mean of 17.8 years (SD 2.5). 32 developed CDW. By logistic regression, while sNfL cNfL and cGFAP showed prognostic merit (AUC 0.72, 0.70, 0.62 respectively), sGFAP did not (AUC 0.5). The combination of cNfL and cGFAP improved CDW prediction compared to either measure considered in isolation (AUC 0.72). The optimal predictive cut-off for CDW (Youden’s index) for cNfL was 596 pg/mL and for cGFAP was 8160 pg/mL. Kaplan–Meier analysis of the cutoff-defined ‘high-high’ and ‘low-low’ combined cNfL and cGFAP groupings improved prediction of CDW compared to either marker individually (Hazard ratio 4.5 (95% CI 2.7–18.3), Logrank P < 0.0001). Cox Proportional Hazards regression demonstrated that high baseline cNfL and cGFAP were independently prognostic of subsequent CDW after adjusting for baseline age, sex, EDSS score and subsequent treatment exposure. Each unit increase in Ln(cNfL) and Ln(cGFAP) was respectively associated with an additional hazard of 2.36 (95% CI 1.12–5.52) and 2.26 (95% CI 1.03–5.21). CSF NfL and GFAP are independently prognostic of long-term clinical worsening in MS, and may represent a complementary pairing.
- 1 February 2018
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 136, 143-149
Ethnic dependent differences in diagnostic accuracy of glycated hemoglobin (HbA1c) in Canadian adults
- 1 February 2018
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 136, 143-149
Ethnic dependent differences in diagnostic accuracy of glycated hemoglobin (HbA1c) in Canadian adults
- 1 January 2018
- Published by Elsevier in Clinical Biochemistry
- Vol. 51, 61-65
Monoclonal protein reference change value as determined by gel-based serum protein electrophoresis
- 1 January 2018
- Published by Elsevier in Clinical Biochemistry
- Vol. 51, 61-65
Monoclonal protein reference change value as determined by gel-based serum protein electrophoresis
- Open Access
- 1 January 2018
- Published by Elsevier in Clinical Biochemistry
- Vol. 51, 10-20
Candidate recommendations for protein electrophoresis reporting from the Canadian Society of Clinical Chemists Monoclonal Gammopathy Working Group
- 1 January 2018
- Published by Elsevier in Clinical Biochemistry
- Vol. 51, 10-20
Open AccessCandidate recommendations for protein electrophoresis reporting from the Canadian Society of Clinical Chemists Monoclonal Gammopathy Working Group
- 14 December 2017
- Published by Springer Nature in Rheumatology International
- Vol. 38 (4) , 641-647
Diagnostic outcome and indications for testing in patients with positive ANCA at a Canadian tertiary care centre
With widespread availability of anti-neutrophil cytoplasmic antibody (ANCA) testing, interpreting positive results has become increasingly challenging. Here, we conducted a retrospective study to evaluate indications for testing and diagnosis of patients with positive ANCA.
- 14 December 2017
- Published by Springer Nature in Rheumatology International
- Vol. 38 (4) , 641-647
Diagnostic outcome and indications for testing in patients with positive ANCA at a Canadian tertiary care centre
With widespread availability of anti-neutrophil cytoplasmic antibody (ANCA) testing, interpreting positive results has become increasingly challenging. Here, we conducted a retrospective study to evaluate indications for testing and diagnosis of patients with positive ANCA.